REG - Allergy Therapeutics - Patients dosed in VLP Peanut PROTECT trial

Allergy TherapeuticsAnnouncement

27/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230327:nRSa2185Ua&default-theme=true

RNS Number : 2185U  Allergy Therapeutics PLC  27 March 2023

 

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

 

Allergy Therapeutics announces dosing of patients has commenced in Phase I
PROTECT trial investigating novel peanut allergy vaccine candidate, VLP Peanut

 

27 March 2023 Allergy Therapeutics (AIM: AGY), the fully integrated commercial
biotechnology company specialising in allergy vaccines, today announces that
the first application of VLP Peanut in peanut allergic patients has commenced
with the Group's innovative, short-course peanut allergy vaccine candidate in
the Phase I PROTECT trial. The first-in-human study is evaluating the safety
and tolerability of VLP Peanut in healthy and peanut allergic adult subjects
and exploring preliminary proof of efficacy.

 

Allergy Therapeutics' wholly-owned, subcutaneous, recombinant vaccine
candidate incorporates novel virus-like particle (VLP) technology, which
enhances the body's immune response by making the peanut allergen resemble an
inactive virus.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the
European Union (Withdrawal) Act 2018.

 

-  ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSELFWLEDSEDD